Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.05B P/E - EPS this Y 24.40% Ern Qtrly Grth -
Income -83.98M Forward P/E - EPS next Y -18.10% 50D Avg Chg -
Sales - PEG - EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -5.00%
Recommedations 1.20 Quick Ratio 19.24 Shares Outstanding 42.92M 52W Low Chg 4.00%
Insider Own 11.90% ROA -21.01% Shares Float 31.28M Beta -
Inst Own 98.96% ROE -32.18% Shares Shorted/Prior 4.55M/3.05M Price 20.81
Gross Margin - Profit Margin - Avg. Volume 512,264 Target Price 85.80
Oper. Margin - Earnings Date - Volume 153,889 Change -2.89%
About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics, Inc. News
04/16/24 With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns
04/03/24 Paragon’s hub-and-spoke biotech model yields another reverse merger
10:01 AM Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
03/25/24 Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
03/12/24 Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
03/07/24 Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
03/06/24 Insiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74m
03/05/24 Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
03/05/24 Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water
03/05/24 Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
03/05/24 Apogee data hint at potential for long-lasting eczema drug
03/05/24 Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
03/04/24 Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
01/02/24 Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
11/21/23 We Think Apogee Therapeutics (NASDAQ:APGE) Can Easily Afford To Drive Business Growth
11/15/23 Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress
11/13/23 Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
10/30/23 Apogee Therapeutics to Participate in Upcoming November Investor Conferences
10/23/23 7 Biotech Stocks to Get In Now Before Investors Catch On
09/27/23 Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
APGE Chatroom

User Image vu_jade Posted - 4 days ago

$APGE swing

User Image MaverikIT Posted - 1 week ago

@DonCorleone77 @net0trader @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @IsabellaDC $APGE

User Image BobBuran Posted - 2 weeks ago

Friday Dow opens -198 and we open +$2,980 with $APGE and $SMXT #stocks

User Image LioBa Posted - 03/31/24

$APGE

User Image DonCorleone77 Posted - 1 month ago

$APGE Apogee announces first participants dosed in Phase 1 trial of APG808 pogee Therapeutics announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous extended half-life monoclonal antibody targeting IL-4Ralpha, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases. APG808 is a novel, SQ extended half-life mAb targeting IL-4Ralpha, a target with clinical validation across eight Type 2 allergic diseases. APG808 has similar binding and femtomolar affinity for IL-4Ralpha as compared to a first-generation mAb, DUPIXENT, and has demonstrated similar inhibition to DUPIXENT across three in vitro assays, which measure downstream functional inhibition of the IL-13/IL-4 pathway. The APG808 Phase 1 trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers. The study will evaluate the safety...

User Image Stock_Titan Posted - 1 month ago

$APGE Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases https://www.stocktitan.net/news/APGE/apogee-therapeutics-announces-first-participants-dosed-in-phase-1-yrjj59qwg0mc.html

User Image basscat12 Posted - 1 month ago

$APGE $DAVE $ELEV New Option listings courtesy @marketchameleonwins

User Image BiotechValues Posted - 1 month ago

@raticals here is how $APGE handled their ph1 data. Probably similar to how SRZN will do it:

User Image MaverikIT Posted - 1 month ago

@net0trader @DonCorleone77 @IsabellaDC @Wigglyick @RonIsWrong $MDGL $CDLX $GCT $APGE ('blow oout of water' data recently) ....

User Image Stock_Titan Posted - 1 month ago

$APGE Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million https://www.stocktitan.net/news/APGE/apogee-therapeutics-inc-announces-closing-of-upsized-public-offering-84skmfx6vcsc.html

User Image martynlucas Posted - 1 month ago

$APGE APGE Stock - Apogee Therapeutics Fundamental Technical Analysis Review LIVE Now on YouTube https://www.youtube.com/watch?v=IsTD63kTA_8 #APGE #Apogee #MartynLucasInvestor

User Image BobBuran Posted - 1 month ago

Monday with Dow closing +47 we close -$3,486 with $SERA and $APGE the spoilers #stocks

User Image MaverikIT Posted - 1 month ago

@RonIsWrong @net0trader @IsabellaDC @DonCorleone77 @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @AboveTheHorizon $APGE - "blow out of water" data - stagging on

User Image Jajhrbdisn Posted - 1 month ago

$APGE this will lose 80% of its value very soon

User Image sixfigures718 Posted - 1 month ago

$APGE $MIRA

User Image OpenOutcrier Posted - 1 month ago

$APGE (-1.9% pre) Apogee Therapeutics (APGE) Prices Upsized 6.77M Share Offering at $62/sh - SI https://ooc.bz/l/27483

User Image OpenOutcrier Posted - 1 month ago

$APGE (-1.9% pre) Apogee Therapeutics (APGE) Prices Upsized 6.77M Share Offering at $62/sh - SI https://ooc.bz/l/27483

User Image DonCorleone77 Posted - 1 month ago

$APGE Apogee Therapeutics 6.77M share Secondary priced at $62.00 The deal size was increased to $420M from $350M and to 6.77M shares offered from 6.0M, pricing below last closing price of $65.24. Jefferies, BofA, Goldman Sachs, TD Cowen and Stifel are acting as joint book running managers for the offering.

User Image Stock_Titan Posted - 1 month ago

$APGE Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering https://www.stocktitan.net/news/APGE/apogee-therapeutics-inc-announces-pricing-of-upsized-420-million-lb2101rixbzx.html

User Image BStudioTrading Posted - 1 month ago

$APGE out

User Image Doorkey Posted - 1 month ago

$APGE Taking sum profit into $SRRK

User Image Tiberius2000 Posted - 1 month ago

$APGE we might have hit the high for the day. Thoughts?

User Image Tiberius2000 Posted - 1 month ago

$APGE it's almost like someone is offload a lot of shares, which is keep this artificially below $65.

User Image BStudioTrading Posted - 1 month ago

$APGE allllll aboard

User Image MaverikIT Posted - 1 month ago

@Wigglyick @DonCorleone77 @RonIsWrong @Cash4freedom @Im_not_Mr_Lebowski @net0trader @IsabellaDC $APGE +4.83 - even after offering "blew out of water"

User Image tradingtwenty Posted - 1 month ago

Top trending industries to keep an eye on this morning: Software - Infrastructure $AISP 🔥 Biotechnology $APGE Software - Application $PHUN Apparel Retail $ANF Discount Stores $TGT Link: https://tradingtwenty.com/dashboard/trending/past

User Image swingingtech Posted - 1 month ago

$APGE https://wallstreetwaves.com/apge-crosses-above-average-analyst-target/

User Image Thestocktraderhubzee Posted - 1 month ago

WATCHLIST MAR 06 2024 $ZG RBC Capital Reiterates Outperform on Zillow Gr, Maintains $66 Price Target $FWRG TD Cowen Maintains Market Perform on First Watch Restaurant Gr, Raises Price Target to $26 $APGE Stifel Maintains Buy on Apogee Therapeutics, Raises Price Target to $95 $HSDT Roth MKM Maintains Buy on Helius Medical Tech, Adjusts Price Target To $24 $TLNE Seaport Global Maintains Buy on Talen Energy, Raises Price Target to $106

User Image swingingtech Posted - 1 month ago

$APGE https://wallstreetwaves.com/apge-stock-earnings-apogee-therapeutics-beats-eps-for-q4-2023/

User Image tradingtwenty Posted - 1 month ago

$APGE has trended 148 times in the past 24 hours (based on 5 minute intervals). Latest article on Mar 05, 2024 06:10 AM: Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results Link: https://tradingtwenty.com/news/381929/apogee-therapeutics-provides-pipeline-progress-and-reports-fourth-quarter-and-full-year-2023-financial-results

Analyst Ratings
Jefferies Buy Mar 6, 24
Stifel Buy Mar 5, 24
Guggenheim Buy Mar 5, 24
Guggenheim Buy Jan 3, 24
BTIG Buy Dec 20, 23
TD Cowen Outperform Aug 8, 23
Wedbush Outperform Aug 8, 23
Stifel Buy Aug 8, 23
Jefferies Buy Aug 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shah Nimish P Director Director Jul 13 Buy 17.00 1,750,000 29,750,000 1,750,000 07/17/23
Fairmount Funds Management LLC Director Director Jul 13 Buy 17 2,941,176 49,999,992 892,529 07/17/23